Sermorelin and ipamorelin are routinely shelved together as “growth hormone peptides,” but they are not variations on one molecule the way two GHRH analogs are. They act on two entirely different receptors, through two different signaling pathways, and they descend from two different parent molecules. Sermorelin is a synthetic fragment of growth hormone–releasing hormone that works at the GHRH receptor; ipamorelin is a synthetic ghrelin mimetic that works at the ghrelin receptor. This article compares them at the level of receptor target, peptide structure, and what the published literature actually measured for each.
Two receptors, two pathways
The cleanest way to separate these compounds is by the receptor each one binds. Both pathways converge on the same downstream output — signaling the pituitary — but they enter through different doors.
- Sermorelin acts at the GHRH receptor (GHRH-R), the same G-protein–coupled receptor on anterior-pituitary somatotrophs that native growth hormone–releasing hormone uses.
- Ipamorelin acts at the growth hormone secretagogue receptor (GHS-R1a) — the ghrelin receptor. Its endogenous ligand is ghrelin, the acylated stomach peptide identified as the natural agonist of this receptor (Kojima et al., Nature, 1999).
Because these are physically distinct receptors with distinct endogenous ligands, the two compounds are not interchangeable and are not redundant. A GHRH analog and a ghrelin mimetic are categorically different tools, and that distinction is the entire point of comparing them. The same GHS-R1a/ghrelin axis is the one we examine in our companion post on ipamorelin vs GHRP-2 vs GHRP-6, where all three compounds share ipamorelin’s receptor but differ in selectivity.
Sermorelin: a GHRH-receptor analog, GRF(1-29)
Sermorelin is the synthetic 1–29 fragment of human growth hormone–releasing hormone, written as GRF(1-29) or GHRH(1-29)-NH2. Native human GHRH is a 44–amino acid peptide, GRF(1-44); the receptor-binding activity is concentrated in the front of that chain, and the first 29 residues are the shortest segment that retains the parent hormone’s signaling activity. Sermorelin is that core fragment, carrying no stabilizing modification.
At the GHRH receptor, agonist binding activates the receptor’s G-protein–coupled signaling cascade in pituitary somatotrophs, which is the mechanism by which native GHRH and its fragments drive growth hormone release. The albumin-bioconjugate study that introduced CJC-1295 confirmed that the hGRF(1-29) fragment acts at the GRF (GHRH) receptor on the anterior pituitary, using that fragment as the activating moiety (Jetté et al., Endocrinology, 2005). Sermorelin is the unmodified version of that same fragment.
As an unprotected peptide, sermorelin is short-lived in circulation. In healthy adult subjects, GHRH(1-29)-NH2 given intravenously was measured to produce a release of growth hormone, with the response characterized over a short pharmacokinetic window consistent with rapid clearance (Wilton et al., Acta Paediatr Suppl, 1993). That is what the study measured in its research subjects — a GHRH-receptor–mediated GH response — reported here as such.
Ipamorelin: a ghrelin mimetic at GHS-R1a
Ipamorelin is a synthetic pentapeptide — five amino-acid residues — with the published sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is not a fragment of GHRH at all. It belongs to the growth-hormone-secretagogue family and functions as a ghrelin mimetic, meaning it activates the same GHS-R1a receptor that the natural hormone ghrelin uses, despite sharing no structural relationship with ghrelin itself.
The defining feature reported for ipamorelin in its introductory pharmacology paper is selectivity. In rats, ipamorelin was measured to release growth hormone with potency comparable to the earlier secretagogue GHRP-6, but — unlike GHRP-6 — it did not produce a significant rise in ACTH or cortisol, and the authors described it as the first selective growth hormone secretagogue on that basis (Raun et al., Eur J Endocrinol, 1998). That selectivity profile — a GH signal at GHS-R1a without the cortisol and prolactin co-stimulation seen with several other secretagogues — is the property most often cited to distinguish it from its GHRP relatives.
Structurally, the pentapeptide was engineered for stability: the N-terminal aminoisobutyric acid (Aib) residue and the D-amino-acid substitutions in the chain are non-standard residues that resist the enzymatic cleavage that rapidly degrades ordinary peptides. The molecule is small, synthetic, and built specifically to act at the ghrelin receptor.
Putting the two side by side
The comparison resolves along three clean axes, and on each one the two compounds sit on opposite sides:
- Receptor target: Sermorelin acts at the GHRH receptor; ipamorelin acts at the ghrelin receptor, GHS-R1a. Different receptors, different endogenous ligands.
- Molecular class and structure: Sermorelin is a 29–residue GHRH fragment, GRF(1-29). Ipamorelin is a 5–residue synthetic ghrelin-mimetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with no sequence relationship to GHRH.
- What the literature measured: For sermorelin, a GHRH-receptor–mediated GH release in healthy subjects (Wilton et al., 1993). For ipamorelin, a GHS-R1a–mediated GH release without significant ACTH/cortisol elevation in rats — the selectivity finding (Raun et al., 1998).
Because they enter through different receptors, the two are sometimes discussed as complementary research tools rather than substitutes — a GHRH-receptor analog and a ghrelin-receptor agonist represent two independent inputs to the same pituitary system. That distinction is the same logic that separates the GHRH-analog family covered in our tesamorelin vs CJC-1295 comparison — where every compound shares sermorelin’s GHRH-receptor pathway — from the ghrelin-mimetic family that ipamorelin belongs to. Sermorelin and ipamorelin straddle that divide: one on each side.
Frequently asked questions
Do sermorelin and ipamorelin work on the same receptor?
No. Sermorelin acts at the GHRH receptor, the same receptor native growth hormone–releasing hormone uses. Ipamorelin acts at the ghrelin receptor, GHS-R1a. They are different receptors with different endogenous ligands, which is the central distinction between the two compounds.
Is ipamorelin a GHRH analog?
No. Ipamorelin is a ghrelin mimetic, not a GHRH analog. It is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that shares no sequence relationship with GHRH. Sermorelin, by contrast, is a direct GHRH fragment.
What is sermorelin, structurally?
Sermorelin is GRF(1-29), the synthetic 1–29 fragment of human GHRH. Native GHRH is the 44–residue GRF(1-44); the first 29 residues are the shortest segment that retains the parent hormone’s receptor-signaling activity, and sermorelin is that fragment with no stabilizing modification.
What does “selective” mean for ipamorelin?
In its introductory pharmacology paper, ipamorelin was measured to release growth hormone in rats without a significant rise in ACTH or cortisol, in contrast to GHRP-6, which raised those hormones. The authors described it as the first selective growth hormone secretagogue on that basis (Raun et al., 1998). It describes the published pharmacology, not an outcome in any individual.
Why are they compared if they are so different?
Both are studied as inputs to the pituitary growth-hormone system, so they are frequently shelved together. The comparison is useful precisely because it surfaces the difference: one is a GHRH-receptor analog and the other is a ghrelin-receptor mimetic, two separate pathways rather than two versions of one compound.
How does ipamorelin relate to the GHRP peptides?
Ipamorelin shares the GHS-R1a (ghrelin) receptor with GHRP-2 and GHRP-6, which is why it is most directly compared with them rather than with sermorelin. The published distinction is selectivity — the absence of significant ACTH/cortisol stimulation in the introductory study. Our companion post on ipamorelin vs GHRP-2 vs GHRP-6 covers that family in detail.
References
- Wilton P, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatrica Supplement. 1993. PMID: 8329825.
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID: 15817669.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822.
- Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PMID: 10604470.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
